Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy — Clinical Trial Site

17 Registered trials

8 Currently recruiting

Organisation

Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy

Location

Otwock, Poland

Identifier

ORG-100049313

Address

Ul. Wladyslawa Stanislawa Reymonta 83/91, 05-400, Poland

Departments

NA
Oddzial III Chorob Pluc z Pododdzialem Onkologicznym
Oddział III – Chorób Płuc z Pododdziałem Onkologicznym
Oddział III Chorób Płuc
Oddział III Chorób Płuc z Pododdziałem Onkologicznym
Oddział III Chorób Płuc z Pododdziałem Onkologicznym Mazowieckiego Centrum
Oddział III Chorób Płuc, Pododdział onkologiczny, ul. Reymonta 83/91
Odział III – Chorób Płuc z Pododziałem Onkologicznym
Oncology
Poradnia Chorób Płuc i Gruźlic, Otwock ul. Reymonta 83/91 Pawilon D
Pulmonary disease department

Clinical trials at this site (17)

Search interface

Study of IBI3009 alone or in combination with other therapies for extensive-stage small cell lung cancer Pending

2025-523972-21-00 Extensive-Stage Small Cell Lung Cancer 7
A Phase 2 Study of Petosemtamab in Combination with Pembrolizumab in Adults with NSCLC Recruiting

2025-522867-13-00 Non Small Cell Lung Cancer 4 2026-04-27
A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Sm… Recruiting

2023-504595-26-00 Non-Small Cell Lung Cancer 4 2023-05-22
A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting

2023-509628-16-00 Small Cell Lung Cancer (SCLC) 5 2026-05-07
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in… Recruiting

2025-521627-78-00 Neoplasms, Lung 5 2026-01-28
A Multicenter, Open-label, Randomized Phase 3 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) vs Investigator Choice of Single-ag… Recruiting

2024-520164-33-00 Non-Small Cell Lung Cancer 5 2025-12-09
HARMONi-3 Recruiting

2024-513087-26-00 Metastatic Non-small Cell Lung Cancer 5 2024-09-10
A Study Evaluating the Overall Survival of Patients with Extensive Stage Small Cell Lung Cancer Receiving Trilaciclib or Placebo prior to To… Recruiting

2022-502357-34-00 Extensive Stage Small Cell Lung Cancer 5 2023-09-27
Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Advanced Non-Small Cell Lung Cancer 10 2021-03-17
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended

2023-507263-19-00 Advanced Non-Small Cell Lung Cancer 5 2020-12-23
An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizu… Ended

2023-506184-34-00 Advanced Malignancies 5 2019-08-09
A trial to learn how well osimertinib (AZD9291) works to prevent cancer from coming back after surgery and how safe it is compared to the pl… Ended

2023-506524-82-00 Stage IB-IIIA non-small cell lung carcinoma, with a cen 5 2015-10-21
A Study of Atezolizumab plus Carboplatin and Etoposide with or Without Tiragolumab (Anti-Tigit Antibody) in Patients with Untreated Extensiv… Ended

2022-502988-37-00 Small cell lung cancer (SCLC) 5 2020-06-19
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer Ended

2024-515051-38-00 Non-small Cell Lung Cancer 5 2018-07-20
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC af… Ended

2023-509137-39-00 Stage IB (T ≥ 4 cm), II and IIIA NSCLC 5 2015-11-06
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Parti… Ended

2023-506859-13-00 Anaplastic lymphoma kinase (ALK)-positive non-small cel 5 2014-09-09
A trial to show the similarity in effects, safety and immune response of FYB206 compared to Keytruda in people with metastatic non-squamous … Ended

2023-509766-37-00 NSCLC 5